Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,467 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.
Jovanović B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA. Jovanović B, et al. Among authors: chen sc. Clin Cancer Res. 2017 Aug 1;23(15):4035-4045. doi: 10.1158/1078-0432.CCR-16-3055. Epub 2017 Mar 7. Clin Cancer Res. 2017. PMID: 28270498 Free PMC article. Clinical Trial.
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer.
Lehmann BD, Abramson VG, Sanders ME, Mayer EL, Haddad TC, Nanda R, Van Poznak C, Storniolo AM, Nangia JR, Gonzalez-Ericsson PI, Sanchez V, Johnson KN, Abramson RG, Chen SC, Shyr Y, Arteaga CL, Wolff AC, Pietenpol JA; Translational Breast Cancer Research Consortium. Lehmann BD, et al. Among authors: chen sc. Clin Cancer Res. 2020 May 1;26(9):2111-2123. doi: 10.1158/1078-0432.CCR-19-2170. Epub 2019 Dec 10. Clin Cancer Res. 2020. PMID: 31822498 Free PMC article. Clinical Trial.
Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.
Shattuck-Brandt RL, Chen SC, Murray E, Johnson CA, Crandall H, O'Neal JF, Al-Rohil RN, Nebhan CA, Bharti V, Dahlman KB, Ayers GD, Yan C, Kelley MC, Kauffmann RM, Hooks M, Grau A, Johnson DB, Vilgelm AE, Richmond A. Shattuck-Brandt RL, et al. Among authors: chen sc. Clin Cancer Res. 2020 Jul 15;26(14):3803-3818. doi: 10.1158/1078-0432.CCR-19-1895. Epub 2020 Mar 31. Clin Cancer Res. 2020. PMID: 32234759 Free PMC article.
Correlative studies investigating effects of PI3K inhibition on peripheral leukocytes in metastatic breast cancer: potential implications for immunotherapy.
Williams CB, Nebhan CA, Yang J, Starnes LS, Yan C, Vilgelm AE, Chen SC, Dan Ayers G, Abramson V, Mayer IA, Richmond A. Williams CB, et al. Among authors: chen sc. Breast Cancer Res Treat. 2020 Nov;184(2):357-364. doi: 10.1007/s10549-020-05846-5. Epub 2020 Aug 7. Breast Cancer Res Treat. 2020. PMID: 32767201 Free PMC article.
Natural History and Characteristics of ERBB2-mutated Hormone Receptor-positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case-control Study from AACR Project GENIE.
LeNoue-Newton ML, Chen SC, Stricker T, Hyman DM, Blauvelt N, Bedard PL, Meric-Bernstam F, Punglia RS, Schrag D, Lepisto EM, Andre F, Smyth L, Dogan S, Yu C, Wathoo C, Levy M, Eli LD, Xu F, Mann G, Lalani AS, Ye F, Micheel CM, Arnedos M. LeNoue-Newton ML, et al. Among authors: chen sc. Clin Cancer Res. 2022 May 13;28(10):2118-2130. doi: 10.1158/1078-0432.CCR-21-0885. Clin Cancer Res. 2022. PMID: 35190802
PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis.
Moyo TK, Kishtagari A, Villaume MT, McMahon B, Mohan SR, Stopczynski T, Chen SC, Fan R, Huo Y, Moon H, Tang Y, Bejan CA, Childress M, Anderson I, Rawling K, Simons RM, Moncrief A, Caza R, Dugger L, Collins A, Dudley CV, Ferrell PB, Byrne M, Strickland SA, Ayers GD, Landman BA, Mason EF, Mesa RA, Palmer JM, Michaelis LC, Savona MR. Moyo TK, et al. Among authors: chen sc. Clin Cancer Res. 2023 Jul 5;29(13):2375-2384. doi: 10.1158/1078-0432.CCR-22-3192. Clin Cancer Res. 2023. PMID: 37036505 Clinical Trial.
4,467 results